TY - JOUR
T1 - Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
T2 - Experience From an Area in Which Betel Nut Chewing Is Popular
AU - Chang, Peter Mu Hsin
AU - Hsieh, Yao Yu
AU - Chen, Ming Huang
AU - Tzeng, Cheng Hwai
AU - Chu, Pen Yuan
AU - Chang, Shyue Yih
AU - Chen, Po Min
AU - Yang, Muh Hwa
N1 - Funding Information:
This study was partially supported by the Taiwan Cancer Clinic Research Foundation.
PY - 2010/6
Y1 - 2010/6
N2 - Background: This study was undertaken to evaluate the efficacy and safety of cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in an area in which betel nut chewing is popular. Methods: Twenty-five patients were enrolled in the study from 2004 to 2008, of whom 13 received first-line cetuximab plus chemotherapy and 12 received second-line cetuximab with or without chemotherapy after the failure of cisplatin. Results: In the first-line chemotherapy group, the overall response [complete response (CR) plus partial response (PR)] was 54% and disease control rate [CR + PR + stable disease (SD)] was 62%. In the cisplatin-failure therapy group, the overall response was 16.7% and disease control rate was 50%. Median overall survival (OS) and time to progression (TTP) in the first-line chemotherapy group were 857 days and 147 days, respectively. In the cisplatin-failure therapy group, median OS and TTP were 371 days and 136 days, respectively. The most common grade 3/4 toxicity in both groups of patients was infection/fever (23% in the first-line group, 50% in the cisplatin-failure group), followed by neutropenia (23% in the first-line group, 25% in the cisplatin-failure group). Conclusion: Cetuximab-based therapy is an effective and safe treatment choice for recurrent/metastatic HNSCC in areas where betel nut chewing is popular.
AB - Background: This study was undertaken to evaluate the efficacy and safety of cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in an area in which betel nut chewing is popular. Methods: Twenty-five patients were enrolled in the study from 2004 to 2008, of whom 13 received first-line cetuximab plus chemotherapy and 12 received second-line cetuximab with or without chemotherapy after the failure of cisplatin. Results: In the first-line chemotherapy group, the overall response [complete response (CR) plus partial response (PR)] was 54% and disease control rate [CR + PR + stable disease (SD)] was 62%. In the cisplatin-failure therapy group, the overall response was 16.7% and disease control rate was 50%. Median overall survival (OS) and time to progression (TTP) in the first-line chemotherapy group were 857 days and 147 days, respectively. In the cisplatin-failure therapy group, median OS and TTP were 371 days and 136 days, respectively. The most common grade 3/4 toxicity in both groups of patients was infection/fever (23% in the first-line group, 50% in the cisplatin-failure group), followed by neutropenia (23% in the first-line group, 25% in the cisplatin-failure group). Conclusion: Cetuximab-based therapy is an effective and safe treatment choice for recurrent/metastatic HNSCC in areas where betel nut chewing is popular.
KW - Betel nut
KW - Cetuximab
KW - Head and neck cancer
KW - Taxane
UR - http://www.scopus.com/inward/record.url?scp=77954285101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954285101&partnerID=8YFLogxK
U2 - 10.1016/S1726-4901(10)70064-2
DO - 10.1016/S1726-4901(10)70064-2
M3 - Article
C2 - 20603086
AN - SCOPUS:77954285101
SN - 1726-4901
VL - 73
SP - 292
EP - 299
JO - Journal of the Chinese Medical Association
JF - Journal of the Chinese Medical Association
IS - 6
ER -